3.2189
price down icon3.28%   -0.1311
 
loading
Kodiak Sciences Inc stock is traded at $3.2189, with a volume of 8,857. It is down -3.28% in the last 24 hours and down -31.65% over the past month. Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
See More
Previous Close:
$3.35
Open:
$3.29
24h Volume:
8,857
Relative Volume:
0.02
Market Cap:
$176.29M
Revenue:
-
Net Income/Loss:
$-197.68M
P/E Ratio:
-0.8561
EPS:
-3.76
Net Cash Flow:
$-158.88M
1W Performance:
-6.09%
1M Performance:
-31.65%
6M Performance:
+22.73%
1Y Performance:
-43.94%
1-Day Range:
Value
$3.18
$3.30
1-Week Range:
Value
$3.1416
$3.697
52-Week Range:
Value
$2.185
$11.60

Kodiak Sciences Inc Stock (KOD) Company Profile

Name
Name
Kodiak Sciences Inc
Name
Phone
650-281-0850
Name
Address
1200 PAGE MILL RD, PALO ALTO, CA
Name
Employee
108
Name
Twitter
@kodiaksciences
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
KOD's Discussions on Twitter

Compare KOD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
KOD
Kodiak Sciences Inc
3.235 176.29M 0 -197.68M -158.88M -3.76
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
513.17 131.61B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
669.51 73.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
618.13 37.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
259.68 32.81B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.68 28.62B 3.81B -644.79M -669.77M -6.24

Kodiak Sciences Inc Stock (KOD) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-09-24 Upgrade Jefferies Hold → Buy
Sep-05-24 Initiated H.C. Wainwright Neutral
Dec-11-23 Resumed Goldman Sell
Nov-17-23 Upgrade CapitalOne Equal Weight → Overweight
Jul-27-23 Downgrade UBS Buy → Neutral
Jul-25-23 Downgrade Chardan Capital Markets Buy → Neutral
Jul-25-23 Downgrade JP Morgan Neutral → Underweight
Jul-24-23 Downgrade CapitalOne Overweight → Equal Weight
Jul-24-23 Downgrade Jefferies Buy → Hold
Nov-15-22 Initiated CapitalOne Overweight
Aug-02-22 Downgrade Citigroup Neutral → Sell
Feb-24-22 Downgrade JP Morgan Overweight → Neutral
Feb-11-22 Initiated Goldman Buy
Feb-02-22 Upgrade JP Morgan Neutral → Overweight
May-11-21 Upgrade ROTH Capital Neutral → Buy
Mar-12-21 Initiated Evercore ISI Outperform
Mar-01-21 Downgrade Barclays Equal Weight → Underweight
Feb-17-21 Downgrade ROTH Capital Buy → Neutral
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Dec-17-20 Initiated Berenberg Buy
Dec-16-20 Initiated UBS Buy
Dec-11-20 Initiated Citigroup Neutral
Nov-30-20 Downgrade JP Morgan Overweight → Neutral
Nov-16-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-13-20 Downgrade Goldman Buy → Neutral
Mar-31-20 Initiated BMO Capital Markets Outperform
Mar-03-20 Initiated Goldman Buy
Feb-18-20 Downgrade Barclays Overweight → Equal Weight
Feb-06-20 Initiated SunTrust Buy
Jan-08-20 Initiated ROTH Capital Buy
Jan-03-20 Initiated Jefferies Buy
Dec-24-19 Initiated JP Morgan Overweight
Oct-15-19 Reiterated Chardan Capital Markets Buy
Feb-20-19 Initiated Chardan Capital Markets Buy
Oct-29-18 Initiated Barclays Overweight
Oct-29-18 Initiated BofA/Merrill Buy
Oct-29-18 Initiated Morgan Stanley Overweight
View All

Kodiak Sciences Inc Stock (KOD) Latest News

pulisher
Mar 19, 2025

Retinal Vein Occlusion Clinical and Non-Clinical Studies, Key - openPR

Mar 19, 2025
pulisher
Mar 18, 2025

KOD Completes Enrollment in Phase III Study for Eye Disease Candidate - MSN

Mar 18, 2025
pulisher
Mar 12, 2025

Diabetic Retinopathy Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Why Palantir (PLTR) Stock Is Up Today - The Globe and Mail

Mar 12, 2025
pulisher
Mar 10, 2025

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy - Marketscreener.com

Mar 10, 2025
pulisher
Mar 10, 2025

Kodiak Sciences completes enrollment in GLOW2 Phase 3 trial - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

KODKodiak Sciences Inc. Latest Stock News & Market Updates - StockTitan

Mar 10, 2025
pulisher
Mar 10, 2025

CDC To Study Vaccines and Autism, Despite Much Research Showing No Link - 69News WFMZ-TV

Mar 10, 2025
pulisher
Mar 10, 2025

Clinical Trial Success: Kodiak Enrolls 250+ Patients for Novel Diabetic Eye Drug - StockTitan

Mar 10, 2025
pulisher
Mar 04, 2025

Diabetic Retinopathy Pipeline 2025: Mechanism of Action, Route - openPR

Mar 04, 2025
pulisher
Feb 25, 2025

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate - Yahoo Finance

Feb 25, 2025
pulisher
Feb 23, 2025

Kodiak Sciences’ Anti-VEGF Could Win Nicely On Retinal Disorders (NASDAQ:KOD) - Seeking Alpha

Feb 23, 2025
pulisher
Feb 20, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Sees Large Increase in Short Interest - MarketBeat

Feb 20, 2025
pulisher
Feb 17, 2025

Elisa Oyj (OTCMKTS:ELMUF) Short Interest Update - Defense World

Feb 17, 2025
pulisher
Feb 17, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Sees Significant Growth in Short Interest - Defense World

Feb 17, 2025
pulisher
Feb 15, 2025

166,843 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Bought by Peapod Lane Capital LLC - MarketBeat

Feb 15, 2025
pulisher
Feb 12, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Feb 12, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Has $209,000 Stock Holdings in Levi Strauss & Co. (NYSE:LEVI) - American Banking and Market News

Feb 08, 2025
pulisher
Feb 08, 2025

SG Americas Securities LLC Has $206,000 Stake in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Feb 08, 2025
pulisher
Feb 06, 2025

Diabetic Retinopathy Market on Track for Major Expansion by 2034, According to DelveInsight | Novartis, Kodiak Sciences Inc., Regenxbio, Perfuse Therapeutics, Hoffmann-La Roche, Boehringer Ingelheim - Barchart

Feb 06, 2025
pulisher
Feb 06, 2025

Diabetic Retinopathy Market on Track for Major Expansion - openPR

Feb 06, 2025
pulisher
Feb 04, 2025

Quarterly Dosing Breakthrough: Kodiak's New Glaucoma Treatment Targets Root Causes - StockTitan

Feb 04, 2025
pulisher
Feb 04, 2025

Kodiak Sciences Inc.'s (NASDAQ:KOD) institutional investors lost 23% over the past week but have profited from longer-term gains - Simply Wall St

Feb 04, 2025
pulisher
Feb 03, 2025

JPMorgan Chase & Co. Purchases 30,735 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Feb 03, 2025
pulisher
Jan 30, 2025

NASA's 2 stuck astronauts take their first spacewalk together - 69News WFMZ-TV

Jan 30, 2025
pulisher
Jan 28, 2025

Polaris, General Motors And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Jan 28, 2025
pulisher
Jan 27, 2025

Age-related Macular Degeneration Treatment Market Size in the 7MM was ~USD 9,840 million in 2023,is further expected to grow by 2034 | DelveInsight - The Globe and Mail

Jan 27, 2025
pulisher
Jan 22, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by Barclays PLC - Defense World

Jan 22, 2025
pulisher
Jan 22, 2025

Gran Tierra Energy Inc. (NYSE:GTE) Shares Bought by Barclays PLC - Defense World

Jan 22, 2025
pulisher
Jan 20, 2025

Short Interest in Kodiak Sciences Inc. (NASDAQ:KOD) Rises By 8.1% - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

Contrasting Cidara Therapeutics (NASDAQ:CDTX) and Kodiak Sciences (NASDAQ:KOD) - Defense World

Jan 20, 2025
pulisher
Jan 19, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Short Interest Update - MarketBeat

Jan 19, 2025
pulisher
Jan 15, 2025

Jane Street Group LLC Has $90,000 Stock Position in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Jan 15, 2025
pulisher
Jan 13, 2025

Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing - MSN

Jan 13, 2025
pulisher
Jan 13, 2025

Why These 24 Stocks Are Skyrocketing - Insider Monkey

Jan 13, 2025
pulisher
Jan 13, 2025

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates - MSN

Jan 13, 2025
pulisher
Jan 10, 2025

Diabetic Retinopathy Global Clinical Trials Review 2024: Region, country (G7 & E7), phase, trial status, End-points Status and Sponsor Type - GlobeNewswire Inc.

Jan 10, 2025
pulisher
Jan 09, 2025

Geode Capital Management LLC Acquires 12,783 Shares of Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Jan 09, 2025
pulisher
Jan 07, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Shares Acquired by Barclays PLC - Defense World

Jan 07, 2025
pulisher
Jan 07, 2025

Kodiak Sciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 07, 2025
pulisher
Jan 02, 2025

Crude Oil Surges 2%; Tesla Shares Plummet - Benzinga

Jan 02, 2025
pulisher
Jan 02, 2025

Kodiak Sciences (NASDAQ:KOD) Shares Down 2.9%Here's What Happened - MarketBeat

Jan 02, 2025
pulisher
Jan 02, 2025

Kodiak Sciences Inc. (NASDAQ:KOD) Shares Purchased by State Street Corp - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

Sanctuary Advisors LLC Reduces Holdings in Kodiak Sciences Inc. (NASDAQ:KOD) - Defense World

Jan 01, 2025
pulisher
Dec 30, 2024

Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail

Dec 30, 2024
pulisher
Dec 28, 2024

Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership - Yahoo Finance

Dec 28, 2024

Kodiak Sciences Inc Stock (KOD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Kodiak Sciences Inc Stock (KOD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
BORGESON JOHN A.
See Remarks
Jun 12 '24
Sale
2.92
1,558
4,549
179,544
$79.70
price up icon 0.37%
$315.01
price down icon 0.88%
$33.42
price up icon 0.09%
$19.60
price down icon 1.10%
$98.86
price up icon 0.44%
biotechnology ONC
$264.15
price down icon 1.17%
Cap:     |  Volume (24h):